4.6 Article

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey

Journal

ECLINICALMEDICINE
Volume 33, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.eclinm.2021.100769

Keywords

-

Funding

  1. Down Syndrome Affiliates in Action
  2. Down Syndrome Medical Interest Group-USA
  3. GiGi's Playhouse
  4. Jerome Lejeune Foundation
  5. LuMind IDSC Foundation
  6. Matthew Foundation
  7. National Down Syndrome Society
  8. National Task Group on Intellectual Disabilities and Dementia Practices
  9. HERCULES Center [NIEHS P30ES019776]
  10. Library Information Technology Services [UL1 TR000424]
  11. Alana USA Foundation
  12. Awakening Angels Foundation
  13. Infectious Diseases Society of America (IDSA)
  14. Centre for Genomic Regulation Severo Ochoa excellence grant
  15. CIBER of Rare Diseases [DURSI 2017SGR595]
  16. Spanish Ministry of Science, Innovation and Universities (MSIU)
  17. Centro de Excelencia Severo Ochoa and CERCA (GenCat)
  18. MRC [MR/S011277/1, MR/S005145/1, MR/R024901/1]
  19. Lumind IDSC
  20. LeJeune Foundation
  21. European Commission [GO-DS21-848077]
  22. National Institute for Health Research (NIHR) Biomedical Research Centre based at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital NHS Foundation Trust
  23. Spanish Fondo de Investigacion Sanitaria-Instituto Carlos III (FIS-ISCIII) [PI19/00634]
  24. Various Grateful Families of Patients
  25. ISCIII
  26. EDER [PT17/0009/0014]
  27. AEI [CEX2018-000782-M]
  28. Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya [2017 SGR 00519]
  29. Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional, Union Europea, Una manera de hacer Europa [PI18/00335, PI14/01126, PI17/01019]
  30. Jerome Lejeune Foundation [1319 Cycle 2019B]
  31. National Institutes of Health (NIA) [1R01AG056850-01A1, R21AG056974, R01AG061566]
  32. Departament de Salut de la Generalitat de Catalunya, Pla Estrategic de Recerca i Innovacio en Salut [SLT006/17/00119]
  33. Fundacio La Marato de TV3 [20141210]
  34. MRC [MR/S011277/1, MR/S005145/1, MR/R024901/1] Funding Source: UKRI
  35. UKRI [MR/S032304/1] Funding Source: UKRI

Ask authors/readers for more resources

Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. The study found that individuals with DS have similar signs/symptoms and risk factors for severe disease course as the general population, but higher rates of medical complications and mortality, especially from age 40.
Background: Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. Methods: The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. Findings: The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0.01), whereas altered consciousness/confusion were more frequent (p < 0.01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus non-DS patients: RR = 2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality. Interpretation: Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. (C) 2021 The Author(s). Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available